<DOC>
	<DOCNO>NCT00633022</DOCNO>
	<brief_summary>This study conduct assess potential anti-inflammatory effect 3-month treatment GW856553 , inflammatory activity within aorta carotid plaque , assess FDG-PET/CT .</brief_summary>
	<brief_title>A Study Evaluate Effects 3 Months Dosing With GW856553 , Assessed FDG-PET/CT Imaging</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Inclusion Criteria Main Study : 1 . Adult male female subject , 50 80 year age , inclusive , body weight &gt; 50 kg body mass index ( BMI ) 19 35 kg/m2 2 . Subjects : experience CV event ( acute coronary syndrome , unstable angina , CABG , PCI , stroke , MI , TIA , carotid endarterectomy ) , clinically stable least 6 month since event , , peripheral vascular disease ( PVD ) , indicate symptoms claudication either positive imaging/treadmill test , reduce ankle branchial pressure index , , diagnosis CAD corroborate stress testing ( exercise pharmacological ) confirm diagnosis atherosclerotic arterial disease Individuals experience CV event PVD give preference enrolment study , also one following : metabolic syndrome , define NCEP ATP III Framingham score &gt; 20 Current smoker ( least 1pack/day ) Wellcontrolled diabetes , define purpose study HbA1c &lt; = 8 % , fast blood glucose &lt; = 126mg/dL ( 7mmol/L ) 3 . Subjects must stable dose statin least 3 month prior first dose study medication . Subjects must capable continue statin therapy screen final follow visit . 4 . Either carotid aortic TBR Â³ 1.6 , measure FDGPET/CT , signify active inflammation . 5 . AST ALT &lt; 2xULN screening ; alkaline phosphatase bilirubin &lt; = 1.5xULN screening ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . 6 . A signed date write informed consent prior admission study 7 . The subject able understand comply protocol requirement , instruction protocolstated restriction . Exclusion Criteria Main Study : 1 . Any medical history clinically relevant abnormality identify screen medical examination , vital sign measurement , 12lead ECG record and/or clinical laboratory examination deem principal investigator and/or medical monitor make subject ineligible inclusion safety concern . 2 . History heart failure define NYHA class II IV know severe LV systolic dysfunction ( EF &lt; 30 % ) regardless symptomatic status 3 . Subjects atrial fibrillation ( AF ) screening exclude . 4 . Insulin control Type 1 Type 2 diabetic 5 . Diabetics fast glucose &gt; 126mg/dL ( 7mmol/L ) HbAc1 level &gt; 8 % , screen . [ note : fasting glucose check first FDGPET scan , glucose &gt; 11mmol/L visit , subject exclude study ] 6 . Positive prestudy hepatitis B surface antigen positive hepatitis C antibody result within 3 month screen . 7 . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . 8 . Renal impairment creatinine clearance &lt; 40 ml/min screening , history kidney transplant history contrast nephropathy . 9 . Subjects rheumatoid arthritis , connective tissue disorder condition know associate active chronic inflammation ( e.g . Inflammatory Bowel Disease ) . 10 . Subjects chronic infection HIV , gingivitis , periodonitis , prostatitis , gastritis , urinary tract infection , active disease , include active tuberculosis history active tuberculosis . 11 . Subjects acute infection , symptom suggestive sinusitis , significant trauma ( burn , fracture ) 12 . History malignancy within past 5 year , nonmelanoma skin cancer . 13 . History skeletal muscle myopathy rhabdomyolysis 14 . Previous exposure GW856553 . 15 . Current use steroid ( inhaled oral ) 16 . Subjects donate 500 mL blood within 56 day prior study medication administration . 17 . Participation clinical study subject receive drug new chemical entity within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose study medication 18 . History alcohol/drug abuse dependence within 12 month study 19 . The subject three month prior history regular alcohol consumption exceed average weekly intake &gt; 28 unit ( average daily intake great 3 unit ) male , average weekly intake &gt; 21 unit ( average daily intake great 2 unit ) female . 1 unit equivalent halfpint ( 284mL ) beer/lager ; 25mL measure spirit 125mL wine ; positive alcohol breath test screen visit 20 . A positive urine test drug abuse ( relate know medication subject take , e.g . codeine pain management ) alcohol screen prior study medication administration . 21 . QTc interval &gt; 450 msec ( use average value triplicate ECGs ) 22 . Subjects exclude participated clinical research study involve radiation past three year 23 . Women must nonchildbearing potential [ i.e . either postmenopausal document hysterectomy tubal ligation sufficient ] . For purpose study , post menopausal define amenorrhoeic great 2 year appropriate clinical profile , e.g . age appropriate , history vasomotor symptom . Postmenopausal status confirm serum urine FSH oestradiol concentration screen , appropriate . Surgical sterility define female hysterectomy and/or bilateral oophorectomy . 24 . An unwillingness male subject abstain sexual intercourse pregnant lactating woman ; unwillingness subject use condom/spermicide addition female partner use another form contraception IUD , diaphragm spermicide , injectable progesterone , subdermal implant tubal ligation woman could become pregnant time first dose study medication 3 month administration last dose study medication . Inclusion Criteria Subjects MRI Substudy 1 . Recent ( approximately last 12 month ) echocardiogram ejection fraction 30 50 % . Exclusion Criteria Subjects MRI Substudy 1 . Contraindication MRI scanning ( assessed local MRI safety questionnaire ) include limited : Intracranial aneurysm clip ( except Sugita ) metallic object , History intra orbital metal fragment remove MD , Pacemakers , implantable cardiac defibrillator nonMR compatible heart valve , Inner ear implant , History claustrophobia MR. 2 . Allergy MRI contrast enhancement agent ( gadolinium ) . 3 . Serum creatinine clearance &lt; 60 mL/min ( At discretion physician , subject may progress formal assessment base 24 hour urine collection serum creatinine limit fall limit .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>FDG-PET/CT , atherosclerosis</keyword>
</DOC>